CEL-SCI (NYSE:CVM) Upgraded at StockNews.com

StockNews.com upgraded shares of CEL-SCI (NYSE:CVM) from a sell rating to a hold rating in a report published on Tuesday morning.

CEL-SCI Stock Performance

Shares of NYSE CVM remained flat at $0.56 during mid-day trading on Tuesday. 166,025 shares of the stock were exchanged, compared to its average volume of 607,387. The stock’s 50 day moving average price is $0.97 and its 200-day moving average price is $1.15. The company has a current ratio of 0.64, a quick ratio of 0.18 and a debt-to-equity ratio of 1.00. CEL-SCI has a 12-month low of $0.54 and a 12-month high of $3.23.

CEL-SCI (NYSE:CVM) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). Equities research analysts forecast that CEL-SCI will post -0.52 earnings per share for the current year.

Institutional Trading of CEL-SCI

A number of hedge funds have recently added to or reduced their stakes in CVM. Tidal Investments LLC purchased a new stake in CEL-SCI in the first quarter worth about $27,000. Calton & Associates Inc. purchased a new stake in CEL-SCI in the third quarter worth about $50,000. Black Diamond Financial LLC lifted its stake in CEL-SCI by 35.8% in the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after acquiring an additional 19,000 shares during the period. Plotkin Financial Advisors LLC purchased a new stake in CEL-SCI in the third quarter worth about $98,000. Finally, Cutter & CO Brokerage Inc. lifted its stake in CEL-SCI by 29.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after acquiring an additional 24,634 shares during the period. 12.08% of the stock is owned by hedge funds and other institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.